QA102 干性 AMD 受试者的 II 期研究 (AMEND)
一项 2 期、双盲、随机、安慰剂对照、剂量反应研究,评估 QA102 在干性年龄相关性黄斑变性 (AMD) 受试者中的安全性和有效性
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 阶段2
联系人和位置
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85021
- Associated Retina Consultants
-
-
California
-
Mountain View、California、美国、94040
- Northern California Retina Vitreous Associates Medical Group
-
Pasadena、California、美国、91107
- California Eye Specialists Medical Group
-
Redlands、California、美国、91107
- California Eye Specialists Medical Group
-
-
Colorado
-
Colorado Springs、Colorado、美国、80909
- Retina Consultants of Southern Colorado, P.C.
-
-
Florida
-
Deerfield Beach、Florida、美国、33064
- Advanced Research
-
Fort Myers、Florida、美国、33912
- National Ophthalmic Research Institute
-
Miami、Florida、美国、33143
- MedEye Associates
-
Pensacola、Florida、美国、32503
- Retina Specialty Institute
-
Pinellas Park、Florida、美国、33782
- Eye Associates of Pinellas
-
Sarasota、Florida、美国、34239
- Sarasota Retina Institute
-
Winter Haven、Florida、美国、33880
- Vitreous and Retina Consultants
-
-
Georgia
-
Marietta、Georgia、美国、30060
- Marietta Eye Clinic
-
-
Illinois
-
Oak Forest、Illinois、美国、60452
- University Retina and Macula Associates
-
-
Louisiana
-
West Monroe、Louisiana、美国、71291
- Northeast Louisiana dba Haik Humble Eye Center
-
-
Maryland
-
Baltimore、Maryland、美国、21209
- The Retina Care Center
-
Hagerstown、Maryland、美国、21740
- Cumberland Valley Retina Consultants
-
Hagerstown、Maryland、美国、21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Worcester、Massachusetts、美国、01605
- Vitreo-Retinal Associates, P.C.
-
-
Missouri
-
St Louis、Missouri、美国、63144
- Retina Research Institute
-
-
Ohio
-
Cincinnati、Ohio、美国、45202
- Velocity Clinical Research
-
-
Oregon
-
Eugene、Oregon、美国、97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie、Pennsylvania、美国、16507
- Erie Retina Research
-
-
Texas
-
Abilene、Texas、美国、79606
- Retina Research Institute of Texas
-
Austin、Texas、美国、78705
- Austin Research Center for Retina
-
Dallas、Texas、美国、75243
- AXIS Clinicals LLC / Retina of North Texas
-
Plano、Texas、美国、75075
- Texas Retina Associates - Plano
-
San Antonio、Texas、美国、78215
- San Antonio Eye Center
-
-
Utah
-
Salt Lake City、Utah、美国、84107
- Rocky Mountain Retina Consultants
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
- Subject must be age ≥50 years at the time of informed consent.
- Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
- Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
- Subject must be willing and able to comply with study procedures and examinations.
Specific to the Study Eye:
-
Subject must have one of the following:
- extensive intermediate-size drusen, or at least 1 large drusen, or
- GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
-
Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).
Specific to Fellow Eye:
- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.
Specific to Both Eyes:
- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.
Key Exclusion Criteria:
- Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
- Subject has ever received gene therapy (for any condition).
- Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
- Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
- Subject had major surgery within 30 days prior to Screening.
Specific to Study Eye:
- Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
- Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
- Subject has endophthalmitis.
- Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
- Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
- Subject has aphakia or absence of the posterior capsule.
- Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)
Specific to Fellow Eye:
Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.
Specific to Either Eye:
- Subject had intraocular surgery with lens replacement within 3 months of Screening.
- Subject has any ophthalmic condition that could require surgery during the study period.
- Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:QA102 200mg group
Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months |
Capsules |
|
实验性的:QA102 400mg group
Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months |
Capsules |
|
安慰剂比较:Placebo group
Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months |
Capsules |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Soft Drusen Volume (mm3)
大体时间:Month 12
|
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set |
Month 12
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean Rate of GA Growth
大体时间:Month 12
|
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline |
Month 12
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (实际的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他研究编号
其他研究编号
- QA102-CS201
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.